Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Astellas Pharma Inc.
  6. News
  7. Summary
    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Astellas Pharma : Receives European Commission Approval for First-in-Class EVRENZOTM (roxadustat) for Adult Patients with Symptomatic Anemia of Chronic Kidney Disease

08/20/2021 EDT

Roxadustat is the first orally administered hypoxia-inducible factor (HIF) prolyl
hydroxylase (PH) inhibitor available for adult patients with anemia associated with
chronic kidney disease in Europe

TOKYO, August 20, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., 'Astellas') and FibroGen, Inc. (Nasdaq: FGEN, CEO: Enrique Conterno, 'FibroGen') today announced that the European Commission (EC) has approved EVRENZOTM (roxadustat) for the treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD).

'We are very pleased EVRENZO has been approved as the first oral HIF-PH inhibitor to treat adult patients with symptomatic anemia associated with CKD in the European Union,' said Steven Benner, M.D., M.H.S., President of Development, Astellas. 'Today's approval provides patients, regardless of dialysis status, with a first-in-class treatment option to address the multifaceted nature of this condition. We look forward to making roxadustat available to adult patients with anemia of CKD in countries across the European Union.'

CKD impacts one in 10 people globally, of whom one in five are affected by anemia.1, 2 Anemia of CKD is often untreated or not treated to target, and is associated with reduced quality of life and progression to adverse cardiovascular (CV) and renal outcomes.3-5

'Anemia is a significant and early complication of CKD that occurs with greater frequency and impact as CKD worsens, affecting patients' day-to-day living, self-care and mobility,' said Jonathan Barratt, Ph.D., FRCP, Consultant Nephrologist and the Mayer Professor of Renal Medicine at the University of Leicester, United Kingdom. 'This approval represents a step forward in providing patients with an efficient and simple option to manage anemia symptoms and maintain target hemoglobin levels to minimize the impact on their quality of life.'

Roxadustat is the first orally administered HIF-PH inhibitor available in the European Union. Roxadustat increases hemoglobin (Hb) levels through a different mechanism of action compared to injectable erythropoiesis-stimulating agents (ESAs) which are typically co-administered with intravenous iron. As a HIF-PH inhibitor, roxadustat activates the body's natural response to reduced oxygen levels in the blood. This response involves the regulation of multiple, coordinated processes that allow management of anemia with a reduced use of intravenous iron.

'HIF-PH inhibitors represent a major advance in the treatment of anemia of CKD,' said Mark Eisner, M.D., M.P.H., Chief Medical Officer, FibroGen. 'Roxadustat provides a novel breakthrough for patients who suffer from this condition.'

This approval follows the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) positive opinion to authorize roxadustat in June6 based on results from a comprehensive pivotal Phase 3 program comprising of eight multicenter and randomized studies, which involved 9,600 patients worldwide.7-12 The results of this program showed roxadustat was efficacious in achieving and maintaining target Hb levels (10-12g/dL) in patients with symptomatic anemia of CKD regardless of dialysis status and irrespective of prior ESA treatment.7-11 The safety profile observed in the roxadustat development program is reflective of the CKD populations studied and comparable to ESAs.7-12

The EC has the authority to approve medicines for European Union member states, as well as in the European Economic Area (EEA) countries Iceland, Norway, Liechtenstein.13

The EC approval of roxadustat triggers a milestone payment of $120 million by Astellas to FibroGen, and FibroGen will also receive royalties based upon European net sales.

Click below for a copy of the full press release

Disclaimer

Astellas Pharma Inc. published this content on 20 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 August 2021 08:10:08 UTC.


© Publicnow 2021
All news about ASTELLAS PHARMA INC.
10/13Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV (enfo..
AQ
10/12ASTELLAS PHARMA : and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV..
PU
10/12SEAGEN : Astellas Complete Enrollment in Cohort K of Study of Padcev, Keytruda Combination..
MT
10/12ASTELLAS PHARMA : Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combini..
BU
10/11ASTELLAS PHARMA : World's First Use of Environmentally Friendly Biomass-based Plastic for ..
PU
10/05PRESS RELEASE : iOmx Therapeutics raises EUR 65 million in Series B round
DJ
10/05PRESS RELEASE : MIG Fonds leads EUR65 million Series B financing of iOmx Therapeutics
DJ
10/04PRESS RELEASE : MIG sells portfolio company Hemovent to MicroPort
DJ
10/01ASTELLAS PHARMA : Juntendo University and Astellas Establish "Direct Reprogramming Regener..
PU
09/30ASTELLAS PHARMA : Corporate Strategic Plan 2021—dedicated to realization
PU
More news
Financials
Sales 2022 1 325 B 11 592 M 11 592 M
Net income 2022 194 B 1 697 M 1 697 M
Net cash 2022 584 B 5 108 M 5 108 M
P/E ratio 2022 18,8x
Yield 2022 2,53%
Capitalization 3 669 B 32 137 M 32 108 M
EV / Sales 2022 2,33x
EV / Sales 2023 2,09x
Nbr of Employees 15 455
Free-Float 98,9%
Chart ASTELLAS PHARMA INC.
Duration : Period :
Astellas Pharma Inc. Technical Analysis Chart | 4503 | JP3942400007 | MarketScreener
Technical analysis trends ASTELLAS PHARMA INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 1 980,00 JPY
Average target price 2 486,15 JPY
Spread / Average Target 25,6%
EPS Revisions
Managers and Directors
Kenji Yasukawa President, CEO & Representative Director
Naoki Okamura CFO, Representative Director & Vice President
Yoshihiko Hatanaka Chairman
Yoshitsugu Shitaka Chief Scientific Officer
Fumiaki Sakurai Head-Business Administration & Compliance
Sector and Competitors
1st jan.Capi. (M$)
ASTELLAS PHARMA INC.24.22%32 494
JOHNSON & JOHNSON2.49%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY40.89%215 657